Reed Jobs’s Yosemite Closes $350 Million Second Fund for Cancer Tech

Yosemite, the investment firm founded by Reed Jobs to transform cancer treatment, has successfully closed its second fund at $350 million. This final close represents a substantial leap from the $200 million first close reported in January, signaling strong limited partner appetite for the firm’s specialized healthcare mandate. By focusing on making cancer a non-lethal condition, Yosemite has carved out a distinct niche that bridges the gap between early-stage laboratory discovery and the rigorous commercialization requirements of the modern biotech market.

The firm’s structure is notably different from traditional Silicon Valley venture shops, as it operates both a for-profit investment arm and a non-profit donor-advised fund. This hybrid model allows Yosemite to provide non-dilutive grants to academic researchers while simultaneously taking equity stakes in the startups that eventually spin out of those same labs. For the venture market, this provides a proprietary pipeline of deal flow that is insulated from the competitive bidding wars often seen in more generalized Series A and B rounds.

Fund II’s $350 million pool arrives at a critical juncture for the life sciences sector, which has faced a more disciplined funding environment compared to the exuberance of 2021. While generalist firms have pulled back from capital-intensive deep tech, specialized vehicles like Yosemite are finding success by emphasizing deep domain expertise and long-term clinical outcomes. The ability to upsize a fund by $150 million in less than a year suggests that LPs are prioritizing managers who can navigate the complex regulatory and scientific hurdles of the oncology space.

From a market perspective, Yosemite’s expansion reflects a broader trend of 'founder-led' philanthropy evolving into institutional-grade venture capital. Much like the Emerson Collective, from which Jobs spun out Yosemite, the firm treats capital as a tool for systemic change rather than just a vehicle for quarterly returns. However, the closing of Fund II at this scale indicates that Yosemite is being viewed by its backers not just as a mission-driven project, but as a serious contender in the competitive biotech asset class.

The deployment of this capital will likely focus on the 'valley of death' in biotech—the period between initial discovery and the Phase II clinical trials that often dictate a company’s survival. By providing a continuum of capital from the grant stage through to late-stage venture rounds, Yosemite reduces the execution risk for other co-investors. This positioning makes the firm an attractive lead investor for startups that require a backer with the patience and technical depth to withstand the long development cycles inherent in cancer therapeutics.

Looking ahead, the success of Yosemite’s second fund will be measured by its ability to translate academic breakthroughs into scalable platforms. As the IPO window for biotech remains selectively open, the firm’s portfolio companies will be under pressure to demonstrate not just scientific viability, but clear paths to reimbursement and market adoption. Investors will be watching closely to see if this $350 million vehicle can produce the clinical wins necessary to justify its hybrid model in an increasingly performance-sensitive venture landscape.